A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
A phase 1/2 trial of FAP-2286 (177Lu / 68Ga) in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.
Overview
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04939610 by Novartis Pharmaceuticals, with 222 participants planned, started 2021-07-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: 68Ga-FAP-2286 and 177Lu-FAP-2286.
Similar pages
not linked directly; found by shared links- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRibociclib (LEE011) Rollover Study for Continued Access
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase IIIb Study of Ribociclib + ET in Early Breast Cancer
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.